1. Cell Cycle/DNA Damage
  2. DNA/RNA Synthesis
    Nucleoside Antimetabolite/Analog
  3. Gemcitabine hydrochloride

Gemcitabine hydrochloride (Synonyms: LY 188011 hydrochloride)

Cat. No.: HY-B0003 Purity: 99.93%
Handling Instructions

Gemcitabine Hydrochloride (LY 188011 hydrochloride) is a DNA synthesis inhibitor which inhibits the growth of BxPC-3, Mia Paca-2, PANC-1, PL-45 and AsPC-1 cells with IC50s of 37.6, 42.9, 92.7, 89.3 and 131.4 nM, respectively.

For research use only. We do not sell to patients.

Gemcitabine hydrochloride Chemical Structure

Gemcitabine hydrochloride Chemical Structure

CAS No. : 122111-03-9

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in Water USD 66 In-stock
Estimated Time of Arrival: December 31
100 mg USD 60 In-stock
Estimated Time of Arrival: December 31
200 mg USD 72 In-stock
Estimated Time of Arrival: December 31
500 mg USD 102 In-stock
Estimated Time of Arrival: December 31
1 g USD 120 In-stock
Estimated Time of Arrival: December 31
5 g   Get quote  
10 g   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 21 publication(s) in Google Scholar

Other Forms of Gemcitabine hydrochloride:

Top Publications Citing Use of Products

    Gemcitabine hydrochloride purchased from MCE. Usage Cited in: Chem Biol Interact. 2018 Jun 25;290:44-51.

    U2OS and MG-63 cells are treated with Gemcitabine, Licoricidin, or Gemcitabine+Licoricidin for 24 h, followed by the determination of active caspse-3 protein level using western blot. Cells without treatment are used as Control.

    Gemcitabine hydrochloride purchased from MCE. Usage Cited in: J Biol Chem. 2017 Jun 2;292(22):9136-9149.

    The plate clone formation of SW480 and SW620 cells with Gemcitabine (8 nM in SW480 and 16 nM in SW620) and/or PX-12 (4 μM in SW480 and 8 μM in SW620).

    Gemcitabine hydrochloride purchased from MCE. Usage Cited in: Naunyn Schmiedebergs Arch Pharmacol. 2019 Jan 25.

    The expression level of p-JAK2, p-STAT3, Bcl-XL, and Mcl-1 in PANC-1 cells is detected by western blot analysis and is all down-regulated in the treatment groups.
    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review


    Gemcitabine Hydrochloride (LY 188011 hydrochloride) is a DNA synthesis inhibitor which inhibits the growth of BxPC-3, Mia Paca-2, PANC-1, PL-45 and AsPC-1 cells with IC50s of 37.6, 42.9, 92.7, 89.3 and 131.4 nM, respectively.

    IC50 & Target

    DNA synthesis[1]

    In Vitro

    MTS assay demonstrates that Gemcitabine (Hydrochloride) at 15 nM, indole-3-carbinol (I3C) at 50 μM and the combination does not affect hTERT-HPNE cell viability. However, treatment with Gemcitabine (Hydrochloride) at 15 nM, I3C at 50 μM and the combination results in 31%, 19% and 72% cell death of BxPC-3 cells, respectively[1].

    In Vivo

    The aim of study is to formulate PLGA nanoparticles (NPs) of Gemcitabine (Hydrochloride, Gemcitabine HCl) for enhanced oral bioavailability via absorption through M cells of Peyer’s patches. Gemcitabine HCl is available as i.v. infusion due to its short half life (8-17 min), rapid metabolism and limited tumor uptake. Gemcitabine loaded PLGA NPs shows 21.47-fold increase in relative bioavailability in comparison to plain drug solution after oral delivery[2]. After i.v. injection of Gemcitabine at doses of 50, 100, and 120, and 300 mg/kg, the highest dose caused considerable body weight loss (p<0.05 at all the time points evaluated, starting from day 3 of first injection) compared with that of the untreated group and complete mortality, whereas 120 mg/kg is determined as the lethal dose 10% (LD10) and 100 mg/kg is considered as the maximal tolerated dose, which does not cause any mortality and a minimal body weight loss[3].

    Clinical Trial
    Molecular Weight




    CAS No.



    OC[[email protected]@H]1[[email protected]](C(F)(F)[[email protected]](N2C(N=C(C=C2)N)=O)O1)O.[H]Cl


    Room temperature in continental US; may vary elsewhere.


    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    Solvent & Solubility
    In Vitro: 

    H2O : ≥ 66.66 mg/mL (222.45 mM)

    DMSO : 46.67 mg/mL (155.74 mM; Need ultrasonic)

    DMF : 2.5 mg/mL (8.34 mM; Need ultrasonic)

    *"≥" means soluble, but saturation unknown.

    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.3371 mL 16.6856 mL 33.3712 mL
    5 mM 0.6674 mL 3.3371 mL 6.6742 mL
    10 mM 0.3337 mL 1.6686 mL 3.3371 mL
    *Please refer to the solubility information to select the appropriate solvent.
    Cell Assay

    Cells (the human pancreatic cell lines, Mia PaCa-2, BxPC-3, AsPC-1, PANC-1, PL-45, and normal pancreatic ductal epithelial cells, hTERT-HPNE cells) are seeded into 96-well plates (3000 cells/well) in triplicate. After overnight incubation, the medium is changed and cells are treated with I3C and/or NBMPR for 24 h. The medium is changed again and cells are cultured in medium containing different concentrations of Gemcitabine in the presence or absence of the same concentrations of I3C and/or NBMPR for 48 h. The cells are then subjected to CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS). Absorbance at 490 nm is measured 2 h after the addition of 20 μL of MTS reagent/well[1].
    The in vitro cytotoxicity of Gemcitabine HCl loaded NPs on Caco-2 cells are performed for 6 h to check the toxicity of NPs during the transport/permeability studies and antiproliferative effect on K562 cells is evaluated for 48 h using the MTT assay. The cells are cultured in 96-well plates at a seeding density of 1.0×104 cells/well for 48 h. Experiments are initiated by replacing the culture medium in each well with 150 μL of sample solutions (0.1, 1, 10, 100 μg/mL) at 37°C in the CO2 incubator. After 4, 24 and 48 h of incubation, the medium is removed and 150 μL of MTT reagent (1 mg/mL) in the serum-free medium is added to each well. The plates are then incubated at 37°C for another 4 h. At the end of the incubation period, the medium is removed and the intracellular formazan is solubilized with 150 μL DMSO and quantified by reading the absorbance at 590 nm on a micro-plate multi-detection instrument, SpectraMax M2 with Soft Max Pro. The medium treated cells serve as controls. Percentage cell viability is calculated based on the absorbance measured relative to the absorbance of cells exposed to the negative control[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration

    Three groups of male Wistar rats (n=6) are subjected to single oral dose bioavailability study. The formulations are administered orally with the aid of a syringe and infant feeding tube. The 1st group is given distilled water, the 2nd group is given a solution of Gemcitabine HCl in distilled water, and the third group received Gemcitabine HCl loaded NPs at a dose of 10 mg/kg. Blood samples (0.3 mL) are drawn by retro-orbital venous plexus puncture with the aid of capillary tubes at 0.5, 1, 2, 4, 24, 48, 72 h post oral dose. The samples are collected in heparinised Eppendorf tubes containing 10 μM tetrahydrouridine, centrifuged at 3400 rpm for 15 min and plasma is collected. To this, 200 μL of Acetonitrile is added and vortexed for 5 min followed by centrifugation at 5000 rpm for 15 min. The organic phase is separated and evaporated under reduced pressure in a vacuum oven. The residue is dissolved in mobile phase (0.15 mL), vortexed for 1 min followed by centrifugation at 13,000 rpm for 5 min. Then 20 μL of supernatant is injected into the HPLC column and analyzed by HPLC.
    DBA/2 mice (5-6 weeks old), weighing approximately 15 to 18 g, are used for the study. The mice are provided with standard mouse food and water ad libitum. The L1210 wt leukemia cells are maintained in vitro, and they are injected intravenously (1×105) into the mice, to develop a systemic metastatic leukemia model. The mice are divided into six groups of seven to eight mice each: untreated, treated with squalene nanoparticles, treated with 100 mg/kg Gemcitabine, treated with 20 mg/kg equivalent SQgem nanoassemblies in Gemcitabine, treated with 100 mg/kg cytarabine, and treated with 100 mg/kg cytarabine every day for 5 days. After injection of leukemia cells (day 0), all groups of mice received the treatment by i.v. injection on days 1, 5, 9, and 14 (i.e., days after injecting leukemia cells), with the exception of the untreated group and the group treated with cytarabine daily by the i.v. route. The mice are monitored regularly for weight differences and survival.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.


    Purity: 99.93%

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2


    GemcitabineLY 188011LY188011LY-188011DNA/RNA SynthesisNucleoside Antimetabolite/AnalogAutophagyInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name



    Applicant name *


    Email address *

    Phone number *


    Organization name *

    Country or Region *


    Requested quantity *


    Bulk Inquiry

    Inquiry Information

    Product name:
    Gemcitabine hydrochloride
    Cat. No.:
    MCE Japan Authorized Agent: